Please login to the form below

Not currently logged in
Email:
Password:

Coreg CR study knocks a quarter off Flamelís shares

Shares in French drug delivery company Flamel Technologies fell by a quarter at the end of last week after a study of its daily controlled-release heart disease drug, Coreg CR, failed demonstrate augmented efficacy when compared with an existing twice-daily treatment, Coreg IR.

Shares in French drug delivery company Flamel Technologies fell by a quarter at the end of last week after a study of its daily controlled-release heart disease drug, Coreg CR, failed demonstrate augmented efficacy when compared with an existing twice-daily treatment, Coreg IR.

The results of the study were published in the Journal of Cardiac Failure.

As a result, Flamelís shares dropped a massive 24.6 per cent (USD 3.12) to settle at USD 9.56. The stock reached a 52-week low of USD 8.96 during the regular trading session.

Coreg IR is sold by GlaxoSmithKline (GSK) in the US, but it is currently experiencing generic competition from Israeli-headquartered Teva and US-based Mylan. Coreg CR was approved by the FDA in October 2006.

Merriman Curhan Ford analysts believe that formulary adoption of Coreg CR will be hindered in the near-term, limiting potential growth of prescriptions. They reaffirmed a "Neutral" rating to Flamel.

Flamel Technologies manufactures Coreg microparticles for GSK under a license agreement. Flamel's drug delivery technology is designed to control absorption of Coreg in the body.

28th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Redline Strategic

We are a healthcare consultancy, specialising in people and experiences. Using innovative research methods to capture the thoughts of real...

Latest intelligence

Australian Flu and the dilemma of naming diseases
...
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
What does a future-proof rep look like?
Businesses can no longer afford to push ahead with the traditional Key Account Management model....

Infographics